Ariad Pharmaceuticals Inc fka ARIA

[andrius]

problem is it was clinically relevant enough for FDA to halt enrollment, hence wall street punishment. lower dose might work but efficiency and side effect questions remain. Only time will tell and time is $$$$$$.

They do not have $2 per in cash, its 1.6s. At current burn rate they'll be out of cash in about 15 months. They will have to either partner or do a secondary offering. With current developments any partner would take on a huge risk and would want to be compensated accordingly. Doubt they'll want to give up any significant portion of potential sales so offering is more than likely. If you think there won't be an offering simply because the stock is down you are highly mistaken. Whether stock is at $20 or $2 is irrelevant, companies raise $ when they need it.